×
About 4,464 results

ALLMedicine™ Liposarcoma Center

Research & Reviews  2,137 results

FUS/TLS suppresses enterovirus replication and promotes antiviral innate immune responses.
https://doi.org/10.1128/JVI.00304-21
Journal of Virology; Chao Xue Y, Seng Ng C et. al.

Apr 8th, 2021 - During viral infection, the dynamic virus-host relationship is constantly in play. Many cellular proteins such as RNA-binding proteins (RBPs) have been shown to mediate antiviral responses during viral infection. Here we reported that the RBP, fus...

Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse...
https://doi.org/10.21873/anticanres.14943
Anticancer Research; Wu NF, Yamamoto J et. al.

Apr 4th, 2021 - Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents. First-line chemotherapy for osteosarcoma has not been improved for many decades. Eribulin has been used to treat breast cancer and liposarcoma in the clinic. ...

Molecular biomarkers of response to eribulin in patients with leiomyosarcoma.
https://doi.org/10.1158/1078-0432.CCR-20-4315
Clinical Cancer Research : an Official Journal of the Ame... Wozniak A, Boeckx B et. al.

Apr 2nd, 2021 - A randomized phase 3 study evaluated the efficacy of eribulin vs dacarbazine in patients with advanced liposarcoma (LPS) and leiomyosarcoma (LMS). Improved overall survival (OS) led to approval of eribulin for LPS, but not for LMS. We explored the...

Symmetric bilateral liposarcoma in an interventional cardiologist.
https://doi.org/10.1016/S1470-2045(21)00119-4
The Lancet. Oncology; Gunsilius E, Bale R et. al.

Apr 1st, 2021 - Symmetric bilateral liposarcoma in an interventional cardiologist.|2021|Gunsilius E,Bale R,Uprimny C,Wolf D,|

Survival analysis and treatment strategies for limb liposarcoma patients with metastasi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021344
Medicine Wang S, Zhou Y et. al.

Mar 31st, 2021 - Limited data exist on patients with limb liposarcoma (LLS) with metastasis at presentation Moreover, the potential prognostic factors of this patient population are poorly documented because of its rarity. Therefore, we conducted this study to eva...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  2,241 results

FUS/TLS suppresses enterovirus replication and promotes antiviral innate immune responses.
https://doi.org/10.1128/JVI.00304-21
Journal of Virology; Chao Xue Y, Seng Ng C et. al.

Apr 8th, 2021 - During viral infection, the dynamic virus-host relationship is constantly in play. Many cellular proteins such as RNA-binding proteins (RBPs) have been shown to mediate antiviral responses during viral infection. Here we reported that the RBP, fus...

Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse...
https://doi.org/10.21873/anticanres.14943
Anticancer Research; Wu NF, Yamamoto J et. al.

Apr 4th, 2021 - Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents. First-line chemotherapy for osteosarcoma has not been improved for many decades. Eribulin has been used to treat breast cancer and liposarcoma in the clinic. ...

Molecular biomarkers of response to eribulin in patients with leiomyosarcoma.
https://doi.org/10.1158/1078-0432.CCR-20-4315
Clinical Cancer Research : an Official Journal of the Ame... Wozniak A, Boeckx B et. al.

Apr 2nd, 2021 - A randomized phase 3 study evaluated the efficacy of eribulin vs dacarbazine in patients with advanced liposarcoma (LPS) and leiomyosarcoma (LMS). Improved overall survival (OS) led to approval of eribulin for LPS, but not for LMS. We explored the...

Symmetric bilateral liposarcoma in an interventional cardiologist.
https://doi.org/10.1016/S1470-2045(21)00119-4
The Lancet. Oncology; Gunsilius E, Bale R et. al.

Apr 1st, 2021 - Symmetric bilateral liposarcoma in an interventional cardiologist.|2021|Gunsilius E,Bale R,Uprimny C,Wolf D,|

Survival analysis and treatment strategies for limb liposarcoma patients with metastasi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021344
Medicine Wang S, Zhou Y et. al.

Mar 31st, 2021 - Limited data exist on patients with limb liposarcoma (LLS) with metastasis at presentation Moreover, the potential prognostic factors of this patient population are poorly documented because of its rarity. Therefore, we conducted this study to eva...

see more →

News  61 results

De-intensification of Radiotherapy Possible in Rare Liposarcoma
https://www.medscape.com/viewarticle/941133

Nov 16th, 2020 - De-intensification of preoperative radiation therapy is both effective and oncologically safe in patients with myxoid liposarcoma, an extremely rare type of soft tissue sarcoma (STS). The lower doses of radiotherapy were also associated with far l...

Primary Site and Other Prognostic Factors Affecting Myxoid Liposarcoma Survivorship
https://www.mdedge.com/fedprac/avaho/article/207824/mixed-topics/primary-site-and-other-prognostic-factors-affecting-myxoid?channel=53
Dickan A, Gootee J et. al.

Sep 9th, 2019 - Background: Myxoid liposarcomas (MLS) are intermediate to high grade liposarcomas, which are the most common type of soft tissue sarcoma. Although MLS most frequently develops in the legs, it can arise in any of the body’s soft tissue adipose.

Primary Anatomical Site as a Prognostic Factor for Pleomorphic Liposarcoma
https://www.mdedge.com/fedprac/avaho/article/207823/mixed-topics/primary-anatomical-site-prognostic-factor-pleomorphic?channel=53
Lee HG, Aurit S et. al.

Sep 9th, 2019 - Background: Pleomorphic liposarcomas is an aggressive, high grade subtype of soft tissue sarcoma representing < 15% of liposarcomas. It most commonly arises in the retroperitoneum and proximal upper extremities.

Surgical Margins and Other Important Prognostic Factors in Dedifferentiated Liposarcoma Survival
https://www.mdedge.com/fedprac/avaho/article/207587/mixed-topics/surgical-margins-and-other-important-prognostic-factors?channel=53
Nguyen K, Gootee J et. al.

Sep 5th, 2019 - Background: Liposarcoma is the most common malignant soft tissue sarcoma (STS). Surgical resection is the most utilized therapeutic option.

Treatment Facility: An Important Prognostic Factor for Dedifferentiated Liposarcoma Survival
https://www.mdedge.com/fedprac/avaho/article/206118/oncology/treatment-facility-important-prognostic-factor/page/0/4?channel=263

Aug 8th, 2019 - Private insurance was the most common form of insurance followed in decreasing order by Medicare, Medicaid, uninsured, and other government insurance. About 42% of the cohort had Medicare, which is a federally funded US insurance program designate.

see more →

Patient Education  21 results see all →